This study is currently not recruiting participants.
Randomized multicenter double-blind placebo-controlled parallel-group phase III study to investigate the efficacy safety and tolerability of 2 different doses of IgPro20 (subcutaneous immunoglobulin) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)
Not Recruiting
18 years - 100 years
All
Phase
N/A
1 Location
Brief description of study.
The purpose of this study is to show how effective two doses of IgPro20 are compared with placebo.
Detailed description of study
The purpose of this study is to show how effective two doses of IgPro20 are compared with placebo.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Polyneuropathy
Age:
18 years - 100 years
Gender: All
Updated on
17 Apr 2014.
Study ID: 1310450026
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
